Bli medlem
Bli medlem

Du är här


TiGenix: Cormorant Asset Management, LLC notifies 5.81% shareholding in TiGenix



Cormorant Asset Management, LLC notifies 5.81% shareholding in TiGenix

Leuven (Belgium) - July 20, 2016, 7:00h CEST
- TiGenix NV (Euronext Brussels: TIG) publishes today the transparency
notification pursuant to Article 14 of the Belgian Law of May 2, 2007
regarding the publication of major holdings in issuers whose securities are
admitted to trading on a regulated market and including various provisions.

Summary of the notification

On July 19, 2016, TiGenix NV received a transparency notification from
Cormorant Asset Management, LLC, following the acquisition of shares on March
14, 2016 by two entities controlled by it (i.e., Cormorant Global Healthcare
Master Fund, LP and CRMA SPV, LP) after which Cormorant Asset Management, LLC
has the discretionary power to exercise 11,756,894 voting rights in TiGenix
NV (5.81% of the voting rights). As a result the 5% threshold was crossed.

Content of the notification by Cormorant Asset Management, LLC

Date of the notification
: July 19, 2016.

Reason of the notification
: acquisition of shares.

Person subject to the notification requirement
: Cormorant Asset Management, LLC, who is a person that notifies alone.

Date on which the threshold was crossed
: March 14, 2016.

Threshold that was crossed
: 5%.

: 202,304,587.

Details of the notification
: following the acquisition of shares, the number of voting rights was as

* Cormorant Asset Management, LLC holds 11,756,894 voting rights in TiGenix
NV (5.81% of voting rights).

Chain of controlled undertakings through which the holdings are effectively
: Cormorant Asset Management, LLC is not a controlled entity. Cormorant Asset
Management, LLC has received the discretionary power to exercise the voting
rights of 11,756,894 TiGenix shares from the following two entities, which
are both controlled by it: Cormorant Global Healthcare Master Fund, LP and

This press release and the above-mentioned transparency notifications can be
consulted on our website:

* press release:;
* notifications:

For more information:

TiGenix NV
Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company
focused on developing and commercializing novel therapeutics from its
proprietary platforms of allogeneic, or donor-derived, expanded stem cells.
Two products from the adipose-derived stem cell technology platform are
currently in clinical development. Cx601 is in Phase III for the treatment of
complex perianal fistulas in Crohn's disease patients. Cx611 has completed a
Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid
arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead
cellular product, AlloCSC-01, is currently in a Phase II clinical trial in
acute myocardial infarction (AMI). In addition, the second product candidate
from the cardiac stem cell-based platform acquired from Coretherapix,
AlloCSC-02, is being developed in a chronic cardiac indication.
On July 4, 2016, we entered into a licensing agreement with Takeda, a large
pharmaceutical company active in gastroenterology, under which Takeda
acquired the exclusive right to commercialize Cx601 for complex perianal
fistulas outside the United States.
TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid
(Spain). For more information, please visit


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TiGenix via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.